Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback